Syros Pharmaceuticals, Inc. · OTC:SYRS
Syros Pharmaceuticals — Investor Presentation (January 2023)
25 slides from Syros Pharmaceuticals's investor presentation, Jan 9, 2023
Slide 1: Advancing Novel Treatments for Hematologic Malignancies
Advancing Novel Treatments for Hematologic Malignancies January 2023 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical dev
Slide 3: Advancing new standards of care for frontline treatment of hematologic malignancies
SIGNIFICANT MARKET OPPORTUNITIES IN FRONTLINE Building infrastructure to target commercially synergistic patient populations that are underserved by existing options MULTIPLE NEAR-TERM CATALYSTS Upcoming opportunities to build momentum and create value, including pivotal SELECT-MDS-1 data and random
Slide 4: Advancing our hematology focused late-stage clinical pipeline
Program Indication Early Clinical IND- Enabling Mid-clinical Pivotal Pivotal Commercial Rights Tamibarotene (oral RARα agonist) Newly diagnosed HR-MDS (w/aza) Newly diagnosed unfit AML (w/ven+aza) SY-2101 (oral ATO) Newly diagnosed APL (w/ATRA) Advancing our hematology focused late-stage clinical pi
Slide 5: Multiple value-driving milestones
SY-2101 in APL Update on dose confirmation study, registration pathway and timing Multiple value-driving milestones Tamibarotene in HR-MDS Tamibarotene in AML Last patient enrolled from SELECT-MDS-1 Phase 3 trial 4Q 23 Pivotal data from SELECT-MDS-1 Phase 3 trial 3Q 24 Initiation of randomized SELEC
Slide 6: Tamibarotene
Tamibarotene Opportunity to establish new SOC in MDS and AML patients with RARA overexpression
Slide 7: Tamibarotene: Compelling profile that addresses large targeted populations
Tamibarotene: Compelling profile that addresses large targeted populations Biologically targeted1 Oral High complete response rates5,6 Rapid time to response5,6 Favorable tolerability4,5,6 Readily combinable4,5,6 No additive myelosuppression5,6 Tamibarotene is a selective and potent RARa agonist1 ✓
Slide 8: Significant unmet need in newly diagnosed HR-MDS
Significant unmet need in newly diagnosed HR-MDS 1DiNardo CD, et al., Cancer. 2022; 2Grob T, et al., Blood. 2022; 3Elihu Estey, et al., Blood 2022; 4Epidemiology projections from DRG Myelodysplastic Syndromes-Landscape & Forecast-Report 2020 and from DRG Acute Myelogenous Leukemia-Landscape & Foreca
Slide 9: Significant unmet need in newly diagnosed unfit AML
Significant unmet need in newly diagnosed unfit AML 1 Ferrara F., Clin Lymphoma Myeloma Leuk. 2011 2Epidemiology projections from DRG Acute Myelogenous Leukemia-Landscape & Forecast-Report 2020; NOTE*: market estimate includes all AML (fit and unfit); 3DiNardo CD, et al., New England Journal of Medi
Slide 10: Encouraging, consistent data from multiple trials support clinical development strategy
Encouraging, consistent data from multiple trials support clinical development strategy 1Data presented at ASH 2017; 2de Botton S., et al. Blood Advances 2022; 3Data presented at ASH 2022 Single-agent tamibarotene in R/R HR-MDS patients1 SELECT-AML-1 safety lead-in evaluating tami/ven/aza in ND unfi
Slide 11: Tamibarotene has a well-characterized and well-tolerated safety profile
Tamibarotene has a well-characterized and well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al. Blood Advances 2022; 4Data presented at ASH 2022 50% CRi 33% CR Data from randomized portion of SELECT-AML-1 trial Phase 2 t
Slide 12: Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS
Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA overexpression Robustly designed, double-blind, placebo-controlled study 90% power to detect a difference in CR rates between experimental and control arms 2:1 randomization with one-sided alpha of 0.025 FDA feedback sup
Slide 13: Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen
Randomized portion of trial* ~80 patients Tamibarotene + venetoclax + azacitidine Venetoclax + azacitidine randomization (1:1) Safety lead-in completed Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen (tami/ven/aza) in ND unfit AML patients with RARA overexpression *Also evaluating triplet as s
Slide 14: SY-2101
SY-2101 Highly synergistic with our hematology portfolio
Slide 15: Significant unmet need in newly diagnosed APL
Significant unmet need in newly diagnosed APL Current standard of care IV ATO oral ATRA >80% Cure rates Treatment burden Current typical course of treatment involves infusions up to Market opportunity for an oral therapy APL accounts for ~10% of all adult AML cases diagnosed in US and Europe annuall
Slide 16: Novel oral form of arsenic trioxide with opportunity to replace standard of care
Novel oral form of arsenic trioxide (ATO) with opportunity to replace standard of care for APL patients Orally bioavailable with exposures consistent with IV ATO Clear development path to approval in frontline APL with potential to leverage emerging data for a more efficient pivotal study Potential
Slide 17: Clear development path to approval in frontline APL
Clear development path to approval in frontline APL with potential to leverage emerging data for a more efficient pivotal study Feedback from the FDA and EMA in the context of original SY-2101 PK data supports a single registration study of approximately 215 patients designed with mCR and EFS as pri
Slide 18: SY-5609
SY-5609 Highly selective and potent oral CDK7 inhibitor
Slide 19: SY-5609: Highly selective and potent oral CDK7 inhibitor
Cell Cycle SY-5609: Highly selective and potent oral CDK7 inhibitor SY-5609 is highly selective with sub-nanomolar potency1 1Marineau JJ et al, 2021, Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7, J Med Chem Data presented in October 2019 at EORTC-NCI-AACR Conference Transcription
Slide 20: Clinical activity in ongoing Phase 1 single agent and combination cohorts
Clinical activity including a confirmed PR and emerging exposure-response relationships in ongoing Phase 1 single agent and combination cohorts *Gemcitabine and nab-paclitaxel administered at approved doses Well tolerated safety profile; MTD has not been reached 30 patients dosed across five levels
Slide 21: Preclinical data support SY-5609 in BRAF-mutant CRC with PDL1 inhibitor
Preclinical data support SY-5609 in BRAF-mutant CRC in combination with PDL1 inhibitor: SY-5609 part of Roche’s Phase 1/1b INTRINSIC trial 67% (20/30) of models demonstrated ≥ 50% tumor growth inhibition 23% (7/30) demonstrated deep responses of ≥ 90% tumor growth inhibition Deep responses enriched
Slide 22: Earlier Stage Programs
Earlier Stage Programs SYR2S
Slide 23: Earlier stage programs
Earlier stage programs Program Indication Drug Discovery IND enabling Clinical stage Commercial Rights SY-5609 (oral CDK7 inhibitor) Metastatic pancreatic cancer (w/chemo) Colorectal cancer (w/atezolizumab)* SY-12882 (oral CDK12 inhibitor) Cancer CDK11 inhibitor Cancer WRN inhibitor Cancer LRF & Nu
Slide 24: Rapidly advancing toward our vision
Rapidly advancing toward our vision Commercial company with medicines that provide a profound benefit for cancer patients Advancing late-stage targeted hematology pipeline Preparing for product launch and commercialization Seeking partnership opportunities for SY-5609 and discovery programs Cash run
Slide 25: SYR2:S
SYR2:S
Syros Pharmaceuticals — Investor Presentation (January 2023) on 6ix